1. How Pfizer s Pipeline Success Can Lift Its Outlook? http://www.trefis.com/stock/pfe/articles/310813/how-pfizers-pipeline-success-can-lift-its-outlook/2015-08-24 by Trefis Team $PFE $JNJ $RHHBY

  2. Opportunity For Roche To Further Strengthen Its Cancer Business Against Evolving C... http://www.trefis.com/stock/rhhby/articles/310271/opportunity-for-roche-to-further-strengthen-its-cancer-business-against-evolving-competition/2015-08-17 by Trefis Team $RHHBY $BMY $MRK

  3. Cry About Remicade, But Not About Merck http://www.trefis.com/stock/mrk/articles/308393/cry-about-remicade-but-not-about-merck/2015-07-31 by Trefis Team $MRK $BMY $RHHBY

  4. Pfizer s Q2 2015 Earnings Were A Turning Point http://www.trefis.com/stock/pfe/articles/308016/pfizers-q2-2015-earnings-were-a-turning-point/2015-07-29 by Trefis Team $PFE $BMY $RHHBY

  5. Why Did Bristol-Myers Squibb s Shares Fall Post Earnings? http://www.trefis.com/stock/bmy/articles/307545/why-did-bristol-myers-squibbs-shares-fall-post-earnings-publish-today/2015-07-27 by Trefis Team $BMY $RHHBY $PFE

  6. Why Roche Is Still Resilient And Doing Well? http://www.trefis.com/stock/rhhby/articles/307182/why-roche-is-still-resilient-and-doing-well/2015-07-24 by Trefis Team $RHHBY $PFE $JNJ

  7. Investors Are Likely To Focus On ‘What s New During Johnson & Johnson s Second Qu... http://www.trefis.com/stock/jnj/articles/304392/investors-are-likely-to-focus-on-whats-new-during-johnson-johnsons-second-quarter-earnings/2015-07-10 by Trefis Team $JNJ $PFE $RHHBY

  8. Roche s Expansion In Africa Is a Good Long Term Move, Though The Immediate Opportu... http://www.trefis.com/stock/rhhby/articles/303157/roches-expansion-in-africa-is-a-good-long-term-move-though-the-immediate-opportunity-is-small/2015-07-02 by Trefis Team $RHHBY $MRK $BMY

  9. Is Pfizer s Failure In Anti-Depressant Pristiq Meaningful? http://www.trefis.com/stock/pfe/articles/301045/is-pfizers-failure-in-anti-depressant-pristiq-meaningful/2015-06-18 by Trefis Team $PFE $RHHBY $MRK

  10. Bristol-Myers Squibb Price Estimate Revised to $65, Here s Why http://www.trefis.com/stock/bmy/articles/301319/bristol-myers-squibb-price-estimate-revised-to-65-heres-why/2015-06-17 by Trefis Team $BMY $RHHBY $MRK

  11. Some Hope For Alzheimer s Patients From Biogen s Data, But Upside For Roche Is Lim... http://www.trefis.com/stock/rhhby/articles/300513/some-hope-for-alzheimers-patients-from-biogens-data-but-upside-for-roche-is-limited/2015-06-12 by Trefis Team $RHHBY $MRK $PFE

  12. Merck s New Filing For Keytruda Is A Meaningful Move http://www.trefis.com/stock/mrk/articles/299962/mercks-new-filing-for-keytruda-is-a-meaningful-move/2015-06-08 by Trefis Team $MRK $RHHBY $BMY

  13. Is A Big Acquisition Is Due For Pfizer? http://www.trefis.com/stock/pfe/articles/298036/is-a-big-acquisition-is-due-for-pfizer/2015-05-28 by Trefis Team $PFE $RHHBY $MRK

  14. Catalysts For Bristol-Myers Squibb s Stock http://www.trefis.com/stock/bmy/articles/298060/catalysts-for-bristol-myers-squibbs-stock/2015-05-27 by Trefis Team $BMY $RHHBY $MRK

  15. Merck & ASCO: It Is All About Keytruda (Pembrolizumab) http://www.trefis.com/stock/mrk/articles/296707/merck-asco-it-is-all-about-keytruda-pembrolizumab/2015-05-21 by Trefis Team $MRK $RHHBY $BMY

  16. ASCO Will Be Important For Roche http://www.trefis.com/stock/rhhby/articles/296335/asco-will-be-important-for-roche/2015-05-20 by Trefis Team $RHHBY $BMY $MRK

  17. FDA s New Warning About Invokana May Not Matter Much For J&J, Let s Focus On Pipel... http://www.trefis.com/stock/jnj/articles/297072/fdas-new-warning-about-invokana-may-not-matter-much-for-jj-lets-focus-on-pipeline-instead/2015-05-19 by Trefis Team $JNJ $RHHBY $BMY

  18. Bristol-Myers Squibb Pins Its Hopes On Eliquis And Immuno-Oncology http://www.trefis.com/stock/bmy/articles/294395/bristol-myers-squibb-pins-its-hopes-on-eliquis-and-immuno-oncology/2015-05-08 by Trefis Team $BMY $RHHBY $JNJ

  19. Is There A Silver Lining For Pfizer Amid Challenging Conditions? http://www.trefis.com/stock/pfe/articles/293930/is-there-silver-lining-for-pfizer-amid-challenging-conditions/2015-05-05 by Trefis Team $PFE $JNJ $RHHBY

  20. Roche s Cancer Segment Is Likely To Remain Strong In Near To Medium Term http://www.trefis.com/stock/rhhby/articles/292074/roches-cancer-segment-is-likely-to-remain-strong-in-near-to-medium-term/2015-04-30 by Trefis Team $RHHBY $BMY $MRK

  21. Roche Earnings Preview: Cancer Drug Growth Will Be Offset By Legacy Declines And A... http://www.trefis.com/stock/rhhby/articles/289541/roche-earnings-preview-cancer-drug-growth-will-be-offset-by-legacy-declines-and-adverse-currency-movement-apr-22/2015-04-21 by Trefis Team $RHHBY $JNJ $PFE

  22. Here Are The Prime Catalysts For Roche s Stock http://www.trefis.com/stock/rhhby/articles/288827/here-are-the-prime-catalysts-for-roches-stock/2015-04-10 by Trefis Team $RHHBY $BMY $MRK

  23. Three Biotechs that Could Radically Change the Practice of Medicine Forever: Wasatch Analyst Jill... http://www.trefis.com/stock/ino/articles/287127/three-biotechs-that-could-radically-change-the-practice-of-medicine-forever-wasatch-analyst-jill-wahleithner/2015-04-01 $INO $RHHBY $NVO

  24. What Does Recent Biosimilar Approval By The FDA Mean? http://www.trefis.com/stock/rhhby/articles/286282/what-does-recent-biosimilar-approval-by-the-fda-mean/2015-03-24 by Trefis Team $BMY $JNJ $MRK

  25. Pfizer Can Add 5%-10% Value By Streamlining Its R&D SPending http://www.trefis.com/stock/pfe/articles/285627/pfizer-can-add-5-10-value-by-streamlining-its-rd-spending/2015-03-19 by Trefis Team $PFE $BMY $RHHBY